Focus on human microbiome to fight liver cirrhosis

22 European institutions join forces in MICROB-PREDICT to improve the prevention and treatment of chronic liver disease (cirrhosis). We aim to identify microbiome-based biomarkers and mechanisms that predict in advance when the body can no longer compensate for the dysfunctional liver (decompensated cirrhosis), when such decompensated cirrhosis will progress to acute-on-chronic liver failure (ACLF), and a patient’s individual treatment response. Based on such biomarkers, we strive to develop novel diagnostic tools for earlier and better patient stratification and to establish personalised and effective treatment strategies.

Learn more

ILC 2021: Symposium „Old and new treatments for patients with advanced cirrhosis”

Very successful symposium on Thursday, 24th June 2021 from 14-15h CEST organised by members of MICROB-PREDICT in the frame of the virtual ILC congress. Topics included:

  • Why and how to modulate the microbiome: example from MICROB-PREDICT study (Shawcross)
  • Old drugs for novel treatment strategies (Posé)
  • Human albumin: from established indications to novel perspectives (Caraceni)
  • System medicine: is it the right track to personalized treatments: example from DECISION study? (Trebicka)

More news

MICROB-PREDICT Symposium connected to EASL School on Hepatology 2021

Symposium on ‘Management of acute-on-chronic liver failure’
Course director: Prof. Wim Laleman
Date: Thursday, 02 September 2021

Read full announcement

More events